Consideration of multiple clinical, cytogenetic, and molecular features identifies TP53 mutation as the most significant prognostic factor in patients with MDS, yet it remains the only marker not routinely assessed in clinical practice. The gene discussed is TP53; the disease is myelodysplastic syndrome.